Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users

International Journal of Epidemiology

Volumn 34, Issue 1, 2005, Pages 152-158

  Wood, Evan ^a,b   Li, Kathy ^a   Miller, Cari L ^a   Hogg, Robert S ^a,b   Montaner, Julio S G ^a,b   Schechter, Martin T ^a,b   Kerr, Thomas ^a  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HIV transmission; HIV AIDS; Injection drug use; Prevention

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE;

COHORT ANALYSIS; DRUG USER; HUMAN IMMUNODEFICIENCY VIRUS; TARGETING;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG USE; ETHNIC DIFFERENCE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK ASSESSMENT; SEROCONVERSION; SEX DIFFERENCE;

ADULT; ATTITUDE TO HEALTH; BRITISH COLUMBIA; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; PATIENT SELECTION; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 14844297045     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/dyh357     Document Type: Article

References (30)

1. Public policy statement on national drug policy. American Society of Addiction Medicine. J Addict Dis 1994;13:231-34.
2. Wall R, Rehm J, Fischer B et al. Social costs of untreated opioid dependence. J Urban Health 2000; 77:688-722.
3. Palepu A, Tyndall MW, Leon H et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ 2001;165:415-20.
4. Wood E, Kerr T, Spittal PM, Tyndall MW, O'Shaughnessy MV, Schechter MT. The healthcare and fiscal costs of the illicit drug use epidemic: the impact of conventional drug control strategies and the impact of a comprehensive approach. BC Med J 2003; 45:130-36.
5. Craib KJ, Spittal PM, Wood E et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 2003;168:19-24.
6. Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002;36:737-42.
7. Tyndall MW, Currie S, Spittal P et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003;17:887-93.
8. Wood E, Tyndall MW, Spittal PM et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ 2001;165:405-10.
9. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998;12:2059-66.
10. Strathdee SA, Galai N, Safaeian M et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a ten year perspective. Arch Intern Med 2001;161: 281-88.
11. Des Jarlais DC, Hagan H, Friedman SR et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995;274:1226-31.
12. Des Jarlais DC, Friedman SR. Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep 1998;113(Suppl.1):182-88.
13. Wood E, Tyndall MW, Spittal P et al. Needle exchange and difficulty with needle access during an ongoing HIV epidemic. Int J Drug Policy 2002;13:95-102.
14. Wood E, Tyndall MW, Spittal PM et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS 2002;16: 41-43.
15. Des Jarlais DC, Marmor M, Paone D et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996;348:987-91.
16. Des Jarlais DC, Friedman SR, Friedmann P et al. HIV/AIDS-related behavior change among injecting drug users in different national settings. AIDS 1995;9:611-17.
17. Des Jarlais DC, Choopanya K, Vanichseni S et al. AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. Am J Public Health 1994;84:452-5.
18. Grund JP, Blanken P, Adriaans NF, Kaplan CD, Barendregt C, Meeuwsen M. Reaching the unreached: targeting hidden IDU populations with clean needles via known user groups. J Psychoactive Drugs 1992; 24:41-47.
19. Des Jarlais DC, Paone D, Milliken J et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999; 353:1657-61.
20. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev 2002;14:367-78.
21. van Griensven F, Supawitkul S, Kilmarx PH et al. Rapid assessment of sexual behavior, drug use, human immunodeficiency virus, and sexually transmitted diseases in northern thai youth using audio-computer-assisted self-interviewing and noninvasive specimen collection. Pediatrics 2001;108:E13.
22. Des Jarlais DC, Padian NS, Winkelstein W Jr. Targeted HIV-prevention programs. N Engl J Med 1994;331:1451-53.
23. Strathdee SA, Patrick DM, Currie SL et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11:F59-65.
24. Spittal PM, Craib KJ, Wood E et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 2002;166:894-99.
25. Latkin CA, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Addiction 1998; 93:1191-97.
26. Celentano D, Vlahov D, Menon A, Polk F. HIV knowledge and attitudes among intravenous drug users: comparisons to the U.S. population and by drug use behaviors. J Drug Issues 1991; 21: 35.
27. Booth RE, Watters JK. How effective are risk-reduction interventions targeting injecting drug users? AIDS 1994;8: 515-24.
28. Latkin CA, Mandell W, Vlahov D, Oziemkowska M, Celentano DD. The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study. Am J Community Psychol 1996;24:341-64.
29. Miller CL, Spittal PM, LaLiberte N et al. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs. J Acquir Immune Defic Syndr 2002;30:335-41.
30. Safaeian M, Brookmeyer R, Vlahov D, Latkin C, Marx M, Strathdee SA. Validity of self-reported needle exchange attendance among injection drug users: implications for program evaluation. Am J Epidemiol 2002;155:169-75.